Mizuho Downgrades BD to Neutral | GenomeWeb

NEW YORK (GenomeWeb News) – Mizuho Securities analyst Peter Lawson today downgraded the stock of Becton Dickinson from Buy to Neutral.

Lawson noted that BD's shares, which closed at $83.94 on the New York Stock Exchange Monday, are within 4 percent of Mizuho's $87 price target. He noted that the firm's stock has risen 9 percent over the past three months and 12 percent over the past six months and no longer trades at a discount to its historical Price-t0-earnings multiple.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: variant linked to obesity risk in Samoans, health of cloned animals, and more.

Researchers explore using genome editing to treat inherited eye diseases, New Scientist reports.

Olympic athletes this summer will also undergo gene doping testing, according to Wired.

A study finds that the lower funding rate seen among women of color is more due to race than gender, according to BuzzFeed News.